Study objective-To determine why, despite 122 randomised controlled trials, there is no consensus about whether the selective serotonin reuptake inhibitors or tricyclic and related antidepressants should be used as first line treatment of depression. Design-Systematic review of all RCTs comparing selective serotonin reuptake inhibitors and tricyclic or heterocyclic antidepressants. Main results-The shortcomings identified in the 122 trials were as follows: (1) there was inadequate description of randomisation, (2) the outcomes used were mainly observer rated measurements of depression, and studies failed to use quality of life measures or perform economic evaluations, (3) doses of tricyclic antidepressants were inadequate, (4) generalisability ofstudies was poor (including a reliance on secondary care settings and inadequate follow up), and (5) there were statistical shortcomings such as low statistical power, failure to use intention to treat analyses, and the tendency to make multiple comparisons. Conclusions-Future RCTs should be designed to inform policy makers and address these methodological shortcomings. (J Epidemiol Community Health 1997;51:354-358) The debate over the use of SSRIs as first line treatment of depression remains unresolved, despite at least six meta-analyses.9 SSRIs are considerably more expensive than tricyclics,10 and it is estimated that the NHS bill for antidepressants would rise from £88 m to £250 m if they were prescribed first line (1993 costs).3 Those recommending wider prescribing of SSRIs claim that the costs would be offset by the advantages of these drugs. The debate in the main has concentrated on differences in how well the two classes of drug are tolerated rather than on efficacy per se. There is some evidence that the SSRIs are better tolerated and this is reflected by slightly lower attrition rates in clinical trials,6 and possibly better compliance in clinical practice. In addition SSRIs are safer in overdose. Policy makers need to know the cost effectiveness of SSRIs in primary care before recommending a prescribing policy for the primary care physicians who carry out most treatment of depression. We aimed to review the methodology of current research in the light of recent recommendations,'2 and to identify methodological weaknesses which may have contributed to current uncertainty.
New treatments in medicine are often expensive. In The debate over the use of SSRIs as first line treatment of depression remains unresolved, despite at least six meta-analyses. 9 SSRIs are considerably more expensive than tricyclics,10 and it is estimated that the NHS bill for antidepressants would rise from £88 m to £250 m if they were prescribed first line (1993 costs). 3 Those recommending wider prescribing of SSRIs claim that the costs would be offset by the advantages of these drugs. The debate in the main has concentrated on differences in how well the two classes of drug are tolerated rather than on efficacy per se. There is some evidence that the SSRIs are better tolerated and this is reflected by slightly lower attrition rates in clinical trials,6 and possibly better compliance in clinical practice. In addition SSRIs are safer in overdose. Policy makers need to know the cost effectiveness of SSRIs in primary care before recommending a prescribing policy for the primary care physicians who carry out most treatment of depression. We aimed to review the methodology of current research in the light of recent recommendations,'2 and to identify methodological weaknesses which may have contributed to current uncertainty.
Methods

LITERATURE SEARCH
We performed a literature search which was validated against an independent search performed by another group (see acknowledgements). The target randomised controlled trials (RCTs) were those comparing four SSRIs (sertraline, fluoxetine, fluvoxamine, and paroxetine) with tricyclic and heterocyclic antidepressants. There is a consensus of opinion in the UK that tricyclics should be prescribed at doses of more than 100 mg. 45 Many studies only reported a range of dosages attained. In general, RCTs from North America used higher doses of tricyclics than those from Europe. It has previously been noted that the doses of tricyclics used were too low and this might have led to a spuriously low estimate of the drop out rate among subjects taking tricyclics. 5 We used the dose of 125 mg as the minimum satisfactory tricyclic dose. Twenty studies used non-tricyclic comparison treatments. Ofthe remaining 102 RCTs, the final dosage was unclear in 22, and the average dose was less than 125 mg in 26 (25%). Thus, in only 54 studies (53%) could one be sure that most subjects were receiving adequate doses of the comparison drug.
GENERALISABILITY OF RESEARCH
Setting of research In the UK, 90% of depressed patients are treated in primary care.4" This is not reflected in these RCTs: only 9 (7%) studies were performed exclusively in primary care. The remainder were conducted in secondary care and many came from teaching hospitals. Thirty nine studies included hospital inpatients with depression. This is a rare group which forms only 1/1000 cases of depression in UK. 46 Apart SSRIs52 over placebo when prescribed for pro-longed periods. Only four of the trials (3%) had a follow up of more than 8 weeks and most compared treatments over 6 weeks (n = 78, 64%).
Differences in costs and benefits of antidepressant therapy may be particularly marked after the acute illness. For example, patients may tolerate side effects during the acute phases of the illness when they perceive a benefit in taking the medication. In contrast, most of the expense of antidepressant prescribing is a result of the longer maintenance period STATISTICAL CONCERNS Sample size and power Most RCTs were small. The median sample size was 64 subjects randomised to receive active treatment (interquartile range, 42-120). The sample size refers to the number ofpatients entered into a study. The mean drop out in most meta-analyses4 has approached one third, therefore the effective sample size in the studies was much less. This glut of small RCTs is partly a consequence of the range of possible comparisons between each of the four SSRIs and numerous tricyclic drugs, but this does not help the policy maker decide which class of drugs should be used as first line treatment.
Small studies lead to type 2 errors. If the median sample size is 32 subjects per treatment group, and one third of subjects drop out of the study, the completer analysis will only include 21 subjects per group. These studies do not have the power to detect even quite important differences between the two treatments. For example, it is widely accepted that 60% of patients treated with a tricyclic antidepressant will recover within six weeks of treatment. A recovery rate of 80% in the SSRIs would be a very important finding, with major clinical significance. To detect such a difference at 80% power and 95% confidence. 91 subjects would be needed in each treatment group. Only 13 (10.6%) of RCTs reviewed here would be able to detect such a difference.
Many of the studies we reviewed did not comment on their low power. One problem of a study comparing two active treatments is the interpretation of a "negative" finding, where no statistically significant difference between treatments is detected. Many of the RCTs we have reviewed reported the failure to find a difference between the two treatments as evidence that they had comparable clinical efficacy, rather than comment on low power. Of 86 studies with fewer than 100 randomised subjects, 51 interpreted a lack of difference in outcome as evidence of comparable efficacy of the two treatments, without mentioning problems of statistical power.
In principle, meta-analysis should overcome the power problems of small trials. However, most trials did not produce elementary statistical information such as means and standard errors of HRSD scores. Many expressed recovery solely in terms of graphical representation and p values. Reporting the size of the observed effect together with confidence intervals was rare. Only two meta-analyses48 have attempted to compare efficacy ratings on the HRSD. In both, data from only a minority of the identified RCTs were used due to this problem.
Statistical analysis It was often difficult to determine the method of statistical analysis in these RCTs. In particular there were frequently ambiguities over the use of intention to treat analysis, in which data from subjects who drop out is collected or missing data is substituted with previous values. Forty four studies did not attempt any form of intention to treat analysis and simply analysed data from those who completed the study. In a further 25 studies it was difficult to be sure exactly what form of analysis had been used. A commonly used method (38 studies) was an analysis of data from the last visit, among subjects who had been evaluated since receiving some randomised treatment. This is not a true intention to treat analysis, since it excludes early drop outs.
The importance of an intention to treat analysis is that it maintains the original random allocation upon which the validity of the RCT relies. It is also more relevant to the health economic evaluation of treatments as it takes account of treatments which are effective but poorly tolerated and thereby provides a better picture of the overall effect of the treatment under study.
Another common statistical fault with these studies is their tendency to perform multiple comparisons which lead to type I errors. According to our definition (see above) 84 studies (69%) made some form of multiple comparison, the most common being multiple endpoints, such as comparing lists of side effects or using various subscales of the HRSD.
Discussion
Most RCTs which compare SSRIs with tricyclic antidepressants are underpowered, use inadequate outcome measures over inadequate follow up periods, are based in settings which limit generalisability to primary care, and do not report an economic analysis. It is perhaps not surprising, therefore, that they have so far been unable to address the concerns of clinicians and policy makers eager to know which drugs should be used as first line treatment of depression.
Why is it that so many studies failed to answer these important questions? The simplest answer is that they were not designed to do so. The emphasis on most of these trials is more to do with comparing efficacy and side effects than determining wider prescribing policy. While this is clearly vital information, it is less easy to justify the number of inadequately powered studies. It is remarkable how uninformative many RCTs have been in determining the direction of future prescribing. 
